Bristol Myers Squibb Company $BMY Shares Purchased by ING Groep NV

ING Groep NV lifted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 227.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 963,133 shares of the biopharmaceutical company’s stock after purchasing an additional 669,447 shares during the quarter. ING Groep NV’s holdings in Bristol Myers Squibb were worth $43,437,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of BMY. Krilogy Financial LLC lifted its stake in shares of Bristol Myers Squibb by 292.0% during the third quarter. Krilogy Financial LLC now owns 45,435 shares of the biopharmaceutical company’s stock worth $2,111,000 after buying an additional 33,843 shares during the period. Advisors Asset Management Inc. increased its position in shares of Bristol Myers Squibb by 2.8% in the 3rd quarter. Advisors Asset Management Inc. now owns 211,930 shares of the biopharmaceutical company’s stock valued at $9,558,000 after acquiring an additional 5,729 shares during the period. Stratos Wealth Advisors LLC raised its stake in Bristol Myers Squibb by 15.4% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 24,568 shares of the biopharmaceutical company’s stock worth $1,108,000 after acquiring an additional 3,279 shares during the last quarter. MQS Management LLC lifted its position in Bristol Myers Squibb by 6.8% during the 3rd quarter. MQS Management LLC now owns 9,349 shares of the biopharmaceutical company’s stock worth $422,000 after acquiring an additional 597 shares during the period. Finally, Providence Capital Advisors LLC grew its stake in Bristol Myers Squibb by 3.2% during the 3rd quarter. Providence Capital Advisors LLC now owns 77,316 shares of the biopharmaceutical company’s stock valued at $3,487,000 after purchasing an additional 2,429 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Wells Fargo & Company restated an “outperform” rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Truist Financial set a $65.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 3rd. Guggenheim restated a “buy” rating and set a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday. Finally, HSBC reiterated a “hold” rating and issued a $53.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $59.20.

Bristol Myers Squibb Trading Up 0.1%

Shares of NYSE:BMY opened at $60.82 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The business has a 50 day moving average of $54.82 and a two-hundred day moving average of $49.20. The company has a market capitalization of $123.81 billion, a PE ratio of 17.63, a PEG ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 70.30%. The firm had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same period last year, the firm earned $1.67 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. The ex-dividend date of this dividend was Friday, January 2nd. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.